Angiotensin Converting Enzyme Inhibitors (ACEIs) Decrease the Progression of Cardiac Fibrosis in Rheumatic Heart...

Area of Science:

• Cardiovascular Medicine
• Immunology
• Rheumatology

Background:

• Rheumatic heart disease (RHD) is a significant global health burden, particularly in developing nations.
• Its pathogenesis involves a complex interplay of host, agent (Group A Streptococcus), and environmental factors.
• Autoimmune responses triggered by GAS infection lead to inflammation and cardiac fibrosis.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying cardiac fibrosis in RHD.
• To investigate the role of Angiotensin II and its interaction with TGF-β and IL-33 signaling pathways.
• To explore the potential cardioprotective effects of Angiotensin converting enzyme inhibitors (ACEIs).

Main Methods:

• The study details the cascade of immune activation, from dendritic cell (DC) antigen presentation to autoreactive T cell activation.
• It describes the signaling pathways involved in cardiac fibrosis, including Mitogen activated protein kinases (MAPKs), TGF-β, and Smad proteins.
• The interaction between Angiotensin II, IL-33, and its receptors (sST2 and ST2L) in promoting or inhibiting fibrosis is examined.

Main Results:

• Angiotensin II promotes RHD pathogenesis by enhancing DC function and stimulating TGF-β-induced fibrosis.
• This process involves increased binding of IL-33 to the decoy receptor sST2, leading to cardiac fibrosis progression.
• ACEIs were shown to inhibit Angiotensin II, reduce TGF-β expression, and promote cardioprotection by allowing IL-33 to bind ST2L.

Conclusions:

• Cardiac fibrosis in RHD is driven by a complex signaling cascade involving Angiotensin II, TGF-β, and IL-33/ST2 interactions.
• ACEIs demonstrate potential as a therapeutic strategy by disrupting this fibrotic pathway and offering cardioprotection.
• Targeting these pathways could lead to novel treatments for RHD and prevent valvular damage.